Modality
Fusion Protein
MOA
CDK4/6i
Target
PSMA
Pathway
Complement
SCDLN
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
Nov 2019
→ Oct 2031
Phase 2Current
NCT03937735
332 pts·LN
2019-11→2031-10·Terminated
NCT08925234
1,816 pts·LN
2021-10→2025-04·Terminated
2,148 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2011mo agoPh3 Readout· LN
2031-10-105.5y awayPh3 Readout· LN
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-04-20 · 11mo ago
LN
Ph3 Readout
2031-10-10 · 5.5y away
LN
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03937735 | Phase 2/3 | LN | Terminated | 332 | SRI-4 |
| NCT08925234 | Phase 2/3 | LN | Terminated | 1816 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |